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ORIGINAL STUDY
Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist,
on vasomotor symptoms in postmenopausal women:
a placebo-controlled, randomized trial
Mike Trower, PhD,1 Richard A. Anderson, MD, PhD,2 Elizabeth Ballantyne, BSc,1
Hadine Joffe, MD, MSc,3 Mary Kerr, PhD,1 and Steve Pawsey, MB, FFPM1
Abstract
Objectives: To evaluate the safety, pharmacokinetics, and preliminary efficacy of NT-814, a dual neurokinin 1,3
antagonist, in postmenopausal women with vasomotor symptoms (hot flashes).
Methods: We completed a double-blind, randomized, placebo-controlled trial in three US clinical research units in
76 postmenopausal women with moderate/severe hot flashes. Participants were randomized to 14 days of once-daily
NT-814 or placebo within each of four sequential dose cohorts; 50, 100, 150, and 300mg. Participants completed
diaries of hot flash frequency and severity and waking due to night sweats before (baseline) and during treatment.
Results: All prespecified efficacy parameters (24-h hot flash frequency and severity, frequency of waking due to
night sweats) decreased in all groups (including placebo). Mean reduction from baseline at week 2 in moderate/
severe hot flash frequency was 37% in the placebo group and, respectively, 24% (P¼ 0.048 vs placebo), 59%
(P¼ 0.155), 84% (P< 0.001) and 66% (P¼ 0.022) in the 50mg, 100mg, 150mg, and 300mg NT-814 groups; in
waking due to night sweats reduction was 20% (P¼ 0.059), 55% (P¼ 0.135), 81% (P< 0.001), and 63%
(P¼ 0.031) in the NT-814 groups and 32% in the placebo group. The improvement with NT-814 150mg
was also evident in the first week of treatment. The most common treatment-related adverse events were mild
somnolence and headache, more frequently in the 300mg group. Safety monitoring identified no concerns.
Conclusions: Once-daily NT-814 (150mg/d) resulted in a rapid, marked improvement in hot flashes and
waking due to night sweats. No safety concerns were identified. Doses up to 300mg were well tolerated.
Key Words: Hot flash – Menopause – Neurokinin 1,3 antagonist – Night sweats.
U
p to 75% of women over 50 experience symptoms
related to menopausal transition—particularly vaso-
motor symptoms (hot flashes and night sweats) and
consequent sleep disturbances—that have a negative impact
on daily activities and quality of life.1-3 Hot flashes are the
most common and distressing symptom and the leading cause
for seeking medical attention during this period.4,5 They are
commonly associated with nighttime awakenings, causing
insomnia and fatigue.6-8 Current treatment options are lim-
ited. Hormone therapy is effective in many women but
associated with increased risk of hormone-dependent cancers
and thrombosis and specifically contraindicated in women
with history of hormone-sensitive cancers.9 Hormone therapy
may also take several months to improve symptoms and may
have limited effects on nighttime awakening.10,11 These
limitations preclude its use in many women. Low-dose
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paroxetine is licensed for use in some countries but has
modest efficacy and some tolerability concerns, as do other
nonhormone therapies.12,13 A safe, effective alternative to
hormonal treatments is urgently needed.
Evidence supports a functional role for neurokinin (NK)
receptor systems in hot flash etiology through hypothalamic
mechanisms.14-16 Kisspeptin, neurokinin B, and dynorphin
(KNDy) neurons in the hypothalamus are hypertrophied in
postmenopausal women and have elevated gene expression
levels of kisspeptin, NKB (endogenous ligand for NK3 recep-
tor), and substance P (SP) (endogenous ligand for NK1
receptor).17-22 The NK3 receptor and its NKB ligand in
particular have been implicated in hot flash etiology.17,18,23,24
Proof-of-concept studies and more recently a fully powered
phase 2b study with NK3 receptor antagonists have provided
clinical evidence that NK3 receptor blockade rapidly reduces
both the number and the severity of hot flashes.14,15,25,26 NK1
receptors and SP may also contribute to the control of
vasomotor symptoms. SP immunoreactivity is frequently
colocalized with kisspeptin and NKB in the infundibular
region22,27 of the hypothalamus. Additionally, in the periph-
ery, NK1 receptor desensitization attenuates cutaneous blood
vessel dilatation28 and infusion of SP causes vasodilatation
and flushing of the face and neck characteristic of postmen-
opausal hot flashes.29 We, therefore, hypothesized that NT-
814, a selective antagonist of both NK1 and NK3 receptors,
would reduce hot flashes and waking due to night sweats in
postmenopausal women and conducted the RELENT-1 study
to evaluate the pharmacokinetics and safety (primary end-
points) and efficacy (exploratory endpoints) of NT-814.
METHODS
RELENT-1 was a multicenter, double-blind, randomized,
placebo-controlled, multiple-ascending-dose study, regis-
tered on Clinical Trials.gov (NCT02865538). The study
was conducted in compliance with Good Clinical Practice
and the principles of the Declaration of Helsinki and in
accordance with a written protocol approved by the institu-
tional review board for each participating center. The study
was completed as planned. Postmenopausal women aged 40
to 65 years with an average of 7 to 20 moderate to severe hot
flashes per day (as recorded in a 2-week patient-reported
baseline diary), <50% change in average daily frequency
between the first and second weeks of the baseline diary, and
no active ongoing health condition that could have caused
difficulty in interpreting hot flash symptoms were enrolled at
three clinical research units in the United States. Menopause
was defined as 12 months of spontaneous amenorrhea or
6 weeks after surgical bilateral oophorectomy, with or with-
out hysterectomy. Participants were required to discontinue
any medications that may have affected the number or
severity of hot flashes or which may have interacted phar-
macokinetically with NT-814 before the start of the baseline
period and were not permitted to take these medications at
any time during the study. All participants provided written
informed consent.
Women were enrolled into four sequential cohorts defined
by the NT-814 daily dose (50, 100, 150, and 300mg). The
study protocol initially specified the dose for the first three
cohorts and allowed an additional two cohorts with further
escalation to as high as 400mg. The study was completed
after the fourth (300mg) cohort because the prespecified NT-
814 plasma concentration limit had been achieved. Within
each cohort participants were randomized in a 3:1 ratio to a
once-daily oral dose of NT-814 or matching placebo in the
morning for 14 days. The randomization code (block size¼ 4)
was computer generated by the Sponsor, communicated via an
interactive Web-based randomization system, and imple-
mented by an unblinded pharmacist at each site who packaged
capsules in a blinded fashion and provided them to the blinded
study staff dispensing medication to participants.
After being admitted the day before the first dose, partic-
ipants remained as residents in the unit for the first 8 days of
dosing (days 1 to 8) for safety, efficacy, and pharmacokinetic
assessment and then continued to take 5 days of medication as
outpatients (days 9-13) before being readmitted to the unit for
the day 14 dose and safety, efficacy, and pharmacokinetic
assessments for 24 hours postdose. Additional visits took
place on days 16 and 17 for safety and pharmacokinetic
assessments, and participants were contacted by telephone
on day 21 for a final safety follow-up.
Participants recalled the number and severity (1¼mild,
2¼moderate, 3¼ severe) of all hot flashes experienced and
recorded these twice daily (morning and evening) in paper
diaries for 2 weeks before treatment start (baseline), for the
14 days of treatment and on the morning of day 15. Partic-
ipants also recorded the number of times that they were
awakened through the night because of night sweats. Safety
was monitored by recording of adverse events through 7 days
after the last dose, physical examinations, vital signs, electro-
cardiograms (ECGs), and clinical laboratory tests.
The primary endpoints of this study were related to safety
assessments and pharmacokinetic parameters (not reported
here), but several exploratory efficacy endpoints were pre-
specified in the protocol and statistical analysis plan, includ-
ing change from baseline in frequency of moderate and severe
hot flashes, hot flash average severity, hot flash severity score
(frequency  severity), and frequency of waking due to night
sweats as recorded in the twice-daily diary.
A formal sample size estimate was not performed for
efficacy, but a pilot study with another NK3 receptor antago-
nist undertaken by one of the authors (RAA) before the
present study was able to distinguish clinically and statisti-
cally significant differences from placebo in hot flash fre-
quency with eight participants per treatment group.14
All statistical tabulation and analyses were performed using
SAS Version 9.3. Efficacy endpoints (frequency and severity
of hot flashes, frequency of waking due to night sweats) were
analyzed according to randomized treatment in participants
who received at least one dose of study drug. Missing data
were not imputed. Data from placebo participants from all
cohorts were pooled for analysis. Statistical hypothesis tests
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and confidence intervals (CIs) were two-sided, using a 0.05
type I error rate. Each analysis was performed using a linear
mixed effects model, with change from baseline as a depen-
dent variable; treatment, week/day, and treatment by week/
day interaction as fixed effects; participant as a random effect;
and baseline (frequency/severity at week 1/day 1) and inter-
action with week/day as covariates. An unstructured covari-
ance matrix was specified for the repeated measures at
postdose time points for each participant. The least-squares
mean and two-sided 95% CIs were calculated for NT-814
versus placebo for each treatment and each post-baseline
week/day. Safety endpoints were analyzed descriptively in
all participants who received at least 1 dose of study drug.
RESULTS
During this study conducted from August 1, 2016 to March
28, 2017, 316 women were screened, and 76 were randomized
and treated (Fig. 1). The high screening exclusion rate resulted
from the relatively stringent selection criteria for general
health required by this first study of NT-814 in women and
the onerous study requirements. All but two participants
completed the study; 1 participant withdrew on day 8 for
personal reasons unrelated to study medication, and one was
lost to follow-up on day 15. All 76 participants were included
in the efficacy and safety analyses. Participants had a mean
age of 55 years; most were white and of Hispanic or Latino
ethnicity (Table 1). Baseline hot flash symptoms were stable
and similar in frequency and severity between all five groups
(4 NT-814 dose levels and placebo) in the 2 weeks before
treatment except that frequency of moderate and severe hot
flashes, severity score, and frequency of waking due to night
sweats were higher in the 50mg NT-814 group than in the
other groups.
The safety profile observed for NT-814 in this study was
favorable. No serious adverse events or adverse events lead-
ing to discontinuation from the study or study drug were
reported. Most adverse events were mild; only one moderate
adverse event was reported in each group. The most common
adverse events were mild somnolence, contact dermatitis
(from ECG electrode attachment), and headache (Table 2).
Somnolence was always mild, usually intermittent, most
commonly reported during the inpatient phase of the study,
and most episodes resolved and did not recur during the
second week of treatment. Overall adverse event incidence
SCREENING
N = 316 129 did not meet eligibility criteria
23 withdrawal by subject
7 physician decision
81 other reasons
Placebo
N = 18
50 mg
N = 15
100 mg
N = 15
150 mg
N = 15
300 mg
N = 13
1 lost to follow-
up aer Day 15
1 withdrawal of subject 
consent aer Day 8
ompleted
N = 17
Completed
N = 14
Completed
N = 15
Completed
N = 15
Completed
N = 13
FIG. 1. Disposition of participants.
TABLE 1. Demographic and baseline characteristics
NT-814 once-daily dose
Characteristic Placebo
N¼ 18
50 mg
N¼ 15
100 mg
N¼ 15
150 mg
N¼ 15
300 mg
N¼ 13
Age (years), mean  SD 55.2 4.08 55.9 5.57 55.3 5.43 56.7 4.37 53.8 3.88
Race, n (%)
White 16 (88.9) 11 (73.3) 11 (73.3) 13 (86.7) 11 (84.6)
Black or African-American 2 (11.1) 4 (26.7) 4 (26.7) 2 (13.3) 2 (15.4)
Ethnicity, n (%)
Hispanic/Latino 13 (72.2) 10 (66.7) 8 (53.3) 10 (66.7) 9 (69.2)
Not Hispanic/Latino 5 (27.8) 5 (33.3) 7 (46.7) 5 (33.3) 4 (30.8)
BMI (kg/m2), mean  SD 28.3 3.71 27.6 3.15 28.0 4.51 28.6 3.35 28.4 4.28
BMI, body mass index; SD, standard deviation.
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was similar in the placebo and 50, 100, and 150mg NT-814
groups and slightly higher in 300mg group. The proportion of
adverse events related to study drug was also highest in the
300mg group. The results of clinical laboratory tests, vital
signs, and ECGs indicated no safety concerns for NT-814.
ECG monitoring included extensive 24-hour Holter monitor-
ing showed no difference between placebo and any dose of
NT-814 in either the incidence or type of arrhythmias.
After the start of treatment, improvements in all efficacy
parameters; frequency (Fig. 2A), severity (Fig. 2B), severity
score (Fig. 2C), and frequency of waking due to night sweats
(Fig. 2D) were observed in all groups (including the placebo
group). Reductions were greater in week 2 of treatment than in
week 1. Mean reduction from baseline at week 2 in moderate/
severe hot flash frequency was 37% in the placebo group
and in the 50mg, 100mg, 150mg, and 300mg NT-814 was,
TABLE 2. Most common adverse events (reported in 10% of participants in any treatment group)
NT-814 once-daily dose
Placebo
N¼ 18
n (%)
50 mg
N¼ 15
n (%)
100 mg
N¼ 15
n (%)
150 mg
N¼ 15
n (%)
300 mg
N¼ 13
n (%)
Any adverse event 13 (72.2) 7 (46.7) 11 (73.3) 10 (66.7) 11 (84.6)
Somnolence 3 (16.7) 5 (33.3) 2 (13.3) 5 (33.3) 9 (69.2)
Contact dermatitisa 5 (27.8) 2 (13.3) 6 (40.0) 5 (33.3) 2 (15.4)
Headache 3 (16.7) 0 5 (33.3) 1 (6.7) 6 (46.2)
Diarrhea 0 1 (6.7) 0 1 (6.7) 3 (23.1)
Pelvic pain 2 (11.1) 3 (20.0) 0 0 0
Viral upper respiratory tract infection 1 (5.6) 0 0 0 3 (23.1)
Dyspepsia 2 (11.1) 0 0 1 (6.7) 0
Alanine aminotransferase increased 0 0 2 (13.3)b 0 0
aFrom ECG electrodes.
bAlanine aminotransferase (ALT) increased to 1.3  upper limit of normal (ULN) on day 8, decreasing to 1.1ULN on day 14 in one participant; and to
2.6  ULN on day 8, decreasing to 1.4ULN on day 14 in the other participant. Four other participants (two receiving placebo and two receiving 300mg
NT-814) had similar changes in ALT that were not reported as adverse events.
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
-8 -7 -6 -5 -4 -3 -2 -1 1 2 3 4 5 6 7 8 9 10 11 12 13 14
M
ea
n 
(+
/-
SE
) D
ai
ly
 F
re
qu
en
cy
 
Day
Placebo 50 mg 100 mg 150 mg 300 mgA  
0.5
1
1.5
2
2.5
1413121110987654321-1-2-3-4-5-6-7-8
M
ea
n 
(+
/-
SE
) D
ai
ly
 S
ev
er
ity
DayB
0
10
20
30
40
1413121110987654321-1-2-3-4-5-6-7-8
M
ea
n 
(+
/-
SE
) D
ai
ly
 S
ev
er
ity
 S
co
re
Day
Placebo 50 mg 100 mg 150 mg 300 mgC
0
1
2
3
4
5
6
7
1413121110987654321-1-2-3-4-5-6-7-8
M
ea
n 
(+
/-
SE
) D
ai
ly
 F
re
qu
en
cy
Day
Placebo 50 mg 100 mg 150 mg 300 mgD
FIG. 2. Daily frequency of: moderate and severe hot flashes (A), Severity of hot flashes (B), daily hot flash severity scorea (C), and waking at night due
to night sweats (D), by day. Data shown are mean  standard error (aseverity score ¼ [number of mild hot flashes  1] þ [number of moderate hot
flashes  2] þ [number of severe hot flashes  3]).
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respectively, 24% (P¼ 0.048 compared to placebo), 59%
(P¼ 0.155), 84% (P< 0.001), and 66% (P¼ 0.022). Mean
reduction in waking due to night sweats was 20% (P¼ 0.059),
55% (P¼ 0.135), 81% (P< 0.001), and 63% (P¼ 0.031) in
the NT-814 groups and 32% in the placebo group. Mean
improvements were greatest in the 150mg and 300mg NT-
814 groups and smallest in the placebo and 50mg NT-814
groups (Table 3). The 95% CIs for the mean differences
showed a good separation between the two higher NT-814
doses and placebo. The changes in severity score mirrored
those of the improvements in hot flash frequency, and the
average severity was improved compared to placebo in
participants treated with 150mg NT-814 but not with the
other doses (Table 2).
Although mean reductions in symptoms in the 50mg group
were significantly smaller than those in the pooled placebo
group, the median changes were in several instances larger on
50mg than on placebo (Table 3). Overall, these data indicate
that NT-814 50mg is an ineffective dose.
The relationship between plasma NT-814 concentrations
and effect was explored in two different pharmacokinetic-
pharmacodynamic models, an inhibitory effect model and a
sigmoid inhibitory effect model, each with a baseline effect
parameter. Both models showed a maximum (plateau) effect
on frequency of hot flashes and waking due to night sweats
with plasma NT-814 concentrations that were achieved with
doses150mg. An example exposure-response model (Emax
model for hot flash frequency in week 2) is shown in Figure 3.
DISCUSSION
RELENT-1 was the first study in postmenopausal women
with hot flash symptoms with NT-814, a novel, nonhormone
dual NK1 and NK3 receptor antagonist that acts by directly
modulating vasomotor neural pathways. Although the study
was small (58 participants who received NT-814 and 18 who
received placebo) and the treatment period was only 2 weeks,
clear and rapid improvements in hot flash frequency and
waking due to night sweats resulted from once-daily oral
treatment with NT-814.
The observed improvements were sufficiently great to have
been clinically meaningful for participants in the 150mg and
300mg groups. The response in the 150mg and 300mg
groups, more than 40% improvement over placebo, is similar
to that reported for the 2 NK3 antagonists evaluated in Phase 2
studies.14,15,25,26 It is also similar to the beneficial effects
reported for hormone therapy over placebo.30,31 Improve-
ments compared to placebo in severity were clearly apparent
for the 150mg dose but less so for the 300mg dose. This
finding most likely reflects the limitations of mean severity as
an outcome without also taking into account the number of hot
flashes. In contrast, severity score, which does take frequency
into account, showed a clear separation from placebo for the
effective doses. Doses up to 300mg were well tolerated, and
no safety concerns were identified.
A feature of the results is an apparent absence of a clear
dose–response relationship on mean changes from baseline.
However, review of the broader dataset suggests that there is a
dose- and/or exposure-ordered response. The apparent advan-
tage of placebo over the 50mg dose is not present when
median values are examined perhaps reflecting the small size
of each treatment group in this early study of NT-814. At the
higher end of the dose–response curve, the mean changes
from baseline indicated that the 150mg dose achieved a better
effect than a 300mg dose. This advantage is again not as
apparent in the median values, and the exposure response
modeling showed that once plasma concentrations of NT-814
equating to those achieved with a 150mg dose are reached
there is a plateau effect.
These findings further support modulation of NK receptors
as a mechanism for treatment for hot flash and other meno-
pause-related symptoms. The hypertrophy of hypothalamic
KNDy neurons in postmenopausal women (with elevated
gene expression levels of kisspeptin, NKB, and SP)17-22 are
a consequence of estrogen withdrawal; in cynomolgus mon-
keys these features can be induced by oophorectomy and
reversed by estrogen replacement.32-34 KNDy neurons branch
extensively within the infundibular nucleus and are linked to
the medial preoptic nucleus, which has been identified as the
estrogen-sensitive thermoregulation control center.23,35 It is
hypothesized that after menopause KNDy neurons are in a
hyperactive state (consistent with the observed hypertrophy)
that disrupts thermoregulation and triggers hot flashes.23 This
hypothesis is supported by clinical studies with other NK3
receptor antagonists that showed NK3 receptor blockade
rapidly reduces both the number and the severity of hot
flashes.14,15,25,26 Additionally, a genome-wide association
study demonstrated that NK3 receptor gene variation may
influence hot flash risk.36 Hot flashes are also a symptom of
carcinoid syndrome, in which SP levels are elevated.37
Although NK1 antagonism alone appears to be ineffective
for hot flashes,38 Phase 2 studies have shown efficacy for NK1
receptor antagonists in mood39-41and primary insomnia,42 so a
compound such as NT-814 that also has NK1 antagonist
properties may also improve sleep and other comorbidities
associated with menopausal symptoms.
Strengths of this study included its randomized, double-
blind, placebo-controlled design, standardized procedures and
assessments, and precise postmenopausal population defini-
tion. However, the relatively stringent selection criteria may
have resulted in a less generalizable study population. Lim-
itations of the study are the small group sizes and short
duration, although both were sufficient to enable a prelimi-
nary assessment of the efficacy of NT-814 as a treatment for
postmenopausal hot flashes to be made before progressing to
larger and longer studies. Although diary recording of hot
flash symptoms is the standard method for symptom assess-
ment, it shares the limitations of other patient-reported out-
come assessments. These assessments are subjective and,
despite randomization and blinding, placebo responses of
50% or more are common.43,44 In RELENT-1, participants
taking placebo had improvements of 37% in mean hot flash
frequency and 15% in mean severity in the second week of
TROWER ET AL
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treatment. On the basis of the results of this small, short
duration study, further evaluation of NT-814 efficacy in
women with bothersome menopausal hot flashes was consid-
ered appropriate, and a Phase 2b study evaluating a range of
doses for 12 weeks of treatment in approximately 200 women
is ongoing (ClinicalTrials.gov NCT03596762).
CONCLUSIONS
In this first study of NT-814 in postmenopausal women with
hot flash symptoms, once-daily treatment resulted in a rapid,
marked improvement in hot flashes and waking due to night
sweats with statistically significant effects at the 150mg and
300mg doses. The effect at these doses was immediate, begin-
ning in the first week of treatment, and also sustained, improv-
ing symptomsmore in the second week of treatment than in the
first. Lower doses (50mg and 100mg once daily) were not
effective. No safety concerns were identified for NT-814.
Doses up to 300mg were well tolerated. Most adverse events
were mild. The most common adverse events were headache
and somnolence that was intermittent and limited in duration.
The findings from the evaluation of this nonhormone dual NK1
and NK3 receptor antagonist support both modulation of NK
receptors as a treatment for hot flashes and other menopause-
related symptoms and the further assessment of NT-814 as a
potential therapy for treating these symptoms.
Acknowledgments: The authors wish to thank Anne McDonough
(McDonough Clinical Research Ltd) for medical writing assistance
and Elise Dunzo (Parexel Quantitative Clinical Development) for
undertaking the exposure-response modeling.
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